Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host

Autores
Cussa, Jorgelina; Juárez , Juliana María; Gómez Costa, Marcos Bruno; Anunziata , Oscar Alfredo
Año de publicación
2021
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release, achieving the required therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work, we show a promising drug storage material for effective encapsulation and controlled release of KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO. Controlled drug delivery systems can achieve precise delivery at the time and place of destination, keeping the concentration of the drug at points in the body within the optimal range and below the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA- 15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects, positively influenced, by the links formed between the host and drug molecules and by diffusion through the host porosity. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
Fil: Juárez, Juliana María. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Anunziata, Oscar Alfredo Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Gómez Costa, Marcos Bruno. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Cussa, Jorgelina. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Materia
Ketorolac
LP-SBA-15
Nanostructured host
Drug-delivering device
Nivel de accesibilidad
acceso abierto
Condiciones de uso
2022-06-02T19:47:00Z
Repositorio
Repositorio Institucional Abierto (UTN)
Institución
Universidad Tecnológica Nacional
OAI Identificador
oai:ria.utn.edu.ar:20.500.12272/6602
Acceder
id RIAUTN_7caaca2b8a38031a6b328f4104512d9f
oai_identifier_str oai:ria.utn.edu.ar:20.500.12272/6602
network_acronym_str RIAUTN
repository_id_str a
network_name_str Repositorio Institucional Abierto (UTN)
spelling Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 hostCussa, JorgelinaJuárez , Juliana MaríaGómez Costa, Marcos BrunoAnunziata , Oscar AlfredoKetorolacLP-SBA-15Nanostructured hostDrug-delivering deviceDrug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release, achieving the required therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work, we show a promising drug storage material for effective encapsulation and controlled release of KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO. Controlled drug delivery systems can achieve precise delivery at the time and place of destination, keeping the concentration of the drug at points in the body within the optimal range and below the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA- 15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects, positively influenced, by the links formed between the host and drug molecules and by diffusion through the host porosity. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.Fil: Juárez, Juliana María. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.Fil: Anunziata, Oscar Alfredo Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.Fil: Gómez Costa, Marcos Bruno. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.Fil: Cussa, Jorgelina. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.2022-06-02T19:47:00Z2022-06-02T19:47:00Z2021info:eu-repo/semantics/conferenceObjectinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciapdfapplication/pdfhttp://hdl.handle.net/20.500.12272/6602-enginfo:eu-repo/semantics/openAccess2022-06-02T19:47:00Zhttp://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 InternacionalOscar A. Anunziata_X_Atribución (Attribution): En cualquier explotación de la obra autorizada por la licencia será necesario reconocer la autoría (obligatoria en todos los casos). _X_No comercial (Non Commercial): La explotación de la obra queda limitada a usos no comerciales. _X_Sin obras derivadas (No Derivate Works): La autorización para explotar la obra no incluye la posibilidad de crear una obra derivada (traducciones, adaptaciones, etc.). _X_Compartir igual (Share Alike): La explotación autorizada incluye la creación de obras derivadas siempre que se mantenga la misma licencia al ser divulgadas.reponame:Repositorio Institucional Abierto (UTN)instname:Universidad Tecnológica Nacional2026-09-24T12:46:37Zoai:ria.utn.edu.ar:20.500.12272/6602instacron:UTNInstitucionalhttp://ria.utn.edu.ar/Universidad públicaNo correspondehttp://ria.utn.edu.ar/oaigestionria@rec.utn.edu.ar; fsuarez@rec.utn.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2026-09-24 12:46:37.542Repositorio Institucional Abierto (UTN) - Universidad Tecnológica Nacionalfalse
dc.title.none.fl_str_mv Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
title Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
spellingShingle Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
Cussa, Jorgelina
Ketorolac
LP-SBA-15
Nanostructured host
Drug-delivering device
title_short Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
title_full Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
title_fullStr Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
title_full_unstemmed Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
title_sort Preparation, characterization and mathematical modeling of keterolac release conteined in LPS BA-15 host
dc.creator.none.fl_str_mv Cussa, Jorgelina
Juárez , Juliana María
Gómez Costa, Marcos Bruno
Anunziata , Oscar Alfredo
author Cussa, Jorgelina
author_facet Cussa, Jorgelina
Juárez , Juliana María
Gómez Costa, Marcos Bruno
Anunziata , Oscar Alfredo
author_role author
author2 Juárez , Juliana María
Gómez Costa, Marcos Bruno
Anunziata , Oscar Alfredo
author2_role author
author
author
dc.subject.none.fl_str_mv Ketorolac
LP-SBA-15
Nanostructured host
Drug-delivering device
topic Ketorolac
LP-SBA-15
Nanostructured host
Drug-delivering device
dc.description.none.fl_txt_mv Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release, achieving the required therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work, we show a promising drug storage material for effective encapsulation and controlled release of KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO. Controlled drug delivery systems can achieve precise delivery at the time and place of destination, keeping the concentration of the drug at points in the body within the optimal range and below the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA- 15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects, positively influenced, by the links formed between the host and drug molecules and by diffusion through the host porosity. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
Fil: Juárez, Juliana María. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Anunziata, Oscar Alfredo Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Gómez Costa, Marcos Bruno. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
Fil: Cussa, Jorgelina. Universidad Tecnológica Nacional. Facultad Regional Córdoba. Centro de Investigación en Nanociencia y Nanotecnología. Córdoba; Argentina.
description Drug-controlled release systems can keep the level of drugs in precise doses in the body above the optimal level and with low toxicity. We propose the LP-SBA-15 nanomaterial as a promising new host for drug delivery systems because of its high biocompatibility, in vivo biodegradability, and low toxicity. Ketorolac-LP-SBA-15 was prepared and characterized by XRD, FTIR, UV-Vis DRS, TEM, and texture analysis, determining the adsorption capacity and its release, achieving the required therapeutic efficacy. The host shows ordered mesoporous nanochannels with a diameter of 11-12 nm, maintaining the structure with the incorporation of Keto. The mechanism of drug release the LP-SBA-15 host was evaluated. Different mathematical models were used to adjust the experimental data, being the Ritger-Peppas model followed by the Weibull model the best ones. In this work, we show a promising drug storage material for effective encapsulation and controlled release of KETO, achieving the required therapeutic efficacy. Studies indicate that KETO was adsorbed on the channel surface of LP-SBA-15 without affecting the structure or chemical composition of KETO. Controlled drug delivery systems can achieve precise delivery at the time and place of destination, keeping the concentration of the drug at points in the body within the optimal range and below the toxicity threshold. The study also demonstrates the storage capacity and release properties of LPSBA- 15 containing KETO. The release of KETO contained in LP-SBA-15 can offer a significant improvement in the controlled release of the drug and the analgesic and anti-inflammatory effects, positively influenced, by the links formed between the host and drug molecules and by diffusion through the host porosity. The promising results we obtained for the release of the drug thoroughly using the new material, reaching a rapid initial release rate, and maintaining a constant rate afterward, allow us to maintain the concentration of the drug in the therapeutic efficacy range, applying it largely to the treatment of diseases that require a rapid response.
publishDate 2021
dc.date.none.fl_str_mv 2021
2022-06-02T19:47:00Z
2022-06-02T19:47:00Z
dc.type.none.fl_str_mv info:eu-repo/semantics/conferenceObject
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
format conferenceObject
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12272/6602
-
url http://hdl.handle.net/20.500.12272/6602
identifier_str_mv -
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
2022-06-02T19:47:00Z
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oscar A. Anunziata
_X_Atribución (Attribution): En cualquier explotación de la obra autorizada por la licencia será necesario reconocer la autoría (obligatoria en todos los casos). _X_No comercial (Non Commercial): La explotación de la obra queda limitada a usos no comerciales. _X_Sin obras derivadas (No Derivate Works): La autorización para explotar la obra no incluye la posibilidad de crear una obra derivada (traducciones, adaptaciones, etc.). _X_Compartir igual (Share Alike): La explotación autorizada incluye la creación de obras derivadas siempre que se mantenga la misma licencia al ser divulgadas.
eu_rights_str_mv openAccess
rights_invalid_str_mv 2022-06-02T19:47:00Z
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Oscar A. Anunziata
_X_Atribución (Attribution): En cualquier explotación de la obra autorizada por la licencia será necesario reconocer la autoría (obligatoria en todos los casos). _X_No comercial (Non Commercial): La explotación de la obra queda limitada a usos no comerciales. _X_Sin obras derivadas (No Derivate Works): La autorización para explotar la obra no incluye la posibilidad de crear una obra derivada (traducciones, adaptaciones, etc.). _X_Compartir igual (Share Alike): La explotación autorizada incluye la creación de obras derivadas siempre que se mantenga la misma licencia al ser divulgadas.
dc.format.none.fl_str_mv pdf
application/pdf
dc.source.none.fl_str_mv reponame:Repositorio Institucional Abierto (UTN)
instname:Universidad Tecnológica Nacional
reponame_str Repositorio Institucional Abierto (UTN)
collection Repositorio Institucional Abierto (UTN)
instname_str Universidad Tecnológica Nacional
repository.name.fl_str_mv Repositorio Institucional Abierto (UTN) - Universidad Tecnológica Nacional
repository.mail.fl_str_mv gestionria@rec.utn.edu.ar; fsuarez@rec.utn.edu.ar
_version_ 1877230924913967104
score 13.265058

Publicaciones similares